Trevi Therapeutics (TRVI) Competitors $10.36 -0.27 (-2.54%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$10.44 +0.09 (+0.82%) As of 10/17/2025 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRVI vs. ACLX, AKRO, CRNX, MENS, NAMS, KYMR, SRRK, VKTX, MIRM, and LNTHShould you be buying Trevi Therapeutics stock or one of its competitors? The main competitors of Trevi Therapeutics include Arcellx (ACLX), Akero Therapeutics (AKRO), Crinetics Pharmaceuticals (CRNX), Jyong Biotech (MENS), NewAmsterdam Pharma (NAMS), Kymera Therapeutics (KYMR), Scholar Rock (SRRK), Viking Therapeutics (VKTX), Mirum Pharmaceuticals (MIRM), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry. Trevi Therapeutics vs. Its Competitors Arcellx Akero Therapeutics Crinetics Pharmaceuticals Jyong Biotech NewAmsterdam Pharma Kymera Therapeutics Scholar Rock Viking Therapeutics Mirum Pharmaceuticals Lantheus Trevi Therapeutics (NASDAQ:TRVI) and Arcellx (NASDAQ:ACLX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment. Which has more risk & volatility, TRVI or ACLX? Trevi Therapeutics has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500. Comparatively, Arcellx has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500. Does the media refer more to TRVI or ACLX? In the previous week, Arcellx had 4 more articles in the media than Trevi Therapeutics. MarketBeat recorded 6 mentions for Arcellx and 2 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 0.65 beat Arcellx's score of -0.26 indicating that Trevi Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcellx 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders believe in TRVI or ACLX? 95.8% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 96.0% of Arcellx shares are owned by institutional investors. 18.3% of Trevi Therapeutics shares are owned by company insiders. Comparatively, 8.4% of Arcellx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has preferable earnings & valuation, TRVI or ACLX? Trevi Therapeutics has higher earnings, but lower revenue than Arcellx. Arcellx is trading at a lower price-to-earnings ratio than Trevi Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTrevi TherapeuticsN/AN/A-$47.91M-$0.42-24.67Arcellx$56.98M84.67-$107.35M-$3.42-25.44 Is TRVI or ACLX more profitable? Trevi Therapeutics has a net margin of 0.00% compared to Arcellx's net margin of -329.93%. Trevi Therapeutics' return on equity of -41.44% beat Arcellx's return on equity.Company Net Margins Return on Equity Return on Assets Trevi TherapeuticsN/A -41.44% -38.21% Arcellx -329.93%-43.04%-27.41% Do analysts rate TRVI or ACLX? Trevi Therapeutics presently has a consensus price target of $21.75, indicating a potential upside of 109.94%. Arcellx has a consensus price target of $113.08, indicating a potential upside of 30.00%. Given Trevi Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Trevi Therapeutics is more favorable than Arcellx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trevi Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89Arcellx 1 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.86 SummaryTrevi Therapeutics beats Arcellx on 10 of the 15 factors compared between the two stocks. Get Trevi Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRVI vs. The Competition Export to ExcelMetricTrevi TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.29B$3.39B$6.09B$10.49BDividend YieldN/A2.28%5.73%4.81%P/E Ratio-24.6722.4484.5227.09Price / SalesN/A429.44568.62202.80Price / CashN/A46.5937.1661.22Price / Book7.9710.4112.246.52Net Income-$47.91M-$52.47M$3.32B$276.75M7 Day Performance3.70%2.32%1.25%1.97%1 Month Performance21.31%11.14%6.28%2.23%1 Year Performance232.05%11.15%59.92%35.58% Trevi Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRVITrevi Therapeutics2.6644 of 5 stars$10.36-2.5%$21.75+109.9%+232.1%$1.29BN/A-24.6720Gap DownACLXArcellx2.3257 of 5 stars$86.23-0.7%$112.69+30.7%-8.7%$4.81B$107.94M-25.2180Analyst ForecastAKROAkero Therapeutics3.6671 of 5 stars$53.66-0.4%$73.38+36.7%+74.7%$4.31BN/A-26.8330Insider TradeCRNXCrinetics Pharmaceuticals4.2868 of 5 stars$44.43-1.1%$74.45+67.6%-29.4%$4.23B$1.04M-10.81210MENSJyong BiotechN/A$55.70+0.8%N/AN/A$4.20BN/A0.0031NAMSNewAmsterdam Pharma2.9523 of 5 stars$37.15+0.3%$42.00+13.1%+91.3%$4.17B$45.56M-22.934News CoverageAnalyst ForecastHigh Trading VolumeKYMRKymera Therapeutics1.0196 of 5 stars$59.89+4.7%$61.26+2.3%+29.4%$4.09B$47.07M-17.26170Analyst ForecastInsider TradeSRRKScholar Rock4.5442 of 5 stars$34.28-13.1%$47.00+37.1%-4.5%$3.79B$33.19M-11.78140Gap DownHigh Trading VolumeVKTXViking Therapeutics3.8869 of 5 stars$33.91+1.0%$86.42+154.8%-48.1%$3.77BN/A-22.1620News CoverageUpcoming EarningsGap DownMIRMMirum Pharmaceuticals3.5938 of 5 stars$72.17-0.7%$76.50+6.0%+87.0%$3.65B$336.89M-59.64140Trending NewsAnalyst ForecastAnalyst RevisionLNTHLantheus4.5387 of 5 stars$54.59+2.0%$74.50+36.5%-51.9%$3.64B$1.53B14.52700Trending NewsAnalyst Revision Related Companies and Tools Related Companies ACLX Alternatives AKRO Alternatives CRNX Alternatives MENS Alternatives NAMS Alternatives KYMR Alternatives SRRK Alternatives VKTX Alternatives MIRM Alternatives LNTH Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRVI) was last updated on 10/18/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trevi Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TRVI Stock Alerts